Quantification of intracellular ACBP/DBI levels.

["Acyl-CoA binding protein (ACBP), also called diazepam-binding inhibitor (DBI), is a ubiquitous protein that can be secreted from cells by an unconventional pathway. Depending on its levels and on its subcellular localization, ACBP\/DBI can regulate lipid metabolism. Several studies have shown that ACBP\/DBI is secreted by an autophagy-dependent mechanism, positioning this catabolic pathway as the mechanism that controls lipid metabolism through the intracellular modulation of the levels of this protein. Autophagy is activated, among other stimuli, when cells have increased energy requirements; this causes a drop in the intracellular ACBP\/DBI levels due to its release into the extracellular space and triggers an increase in the lipid catabolism. Conversely, when autophagy is inhibited, during pathological (obesity) or physiological (after-meal) situations, the intracellular levels of ACBP\/DBI increase resulting in the activation of lipid anabolism, this effect has been demonstrated to be the link between obesity and autophagy inhibition. Here, we detail three different protocols for the detection of the ACBP\/DBI levels by immunofluorescence, image flow cytometry or immunoblot techniques, which allow the quantification of ACBP\/DBI levels and, indirectly, its autophagy-dependent release.",{"copyright":"Copyright \u00a9 2021 Elsevier Inc. All rights reserved."}]